USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

ABSTRACT

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the benefit of U.S. ProvisionalApplication Ser. No. 62/172,690, filed on Jun. 8, 2015, which is hereinincorporated by reference for completeness of disclosure.

STATEMENT AS TO RIGHTS TO INVENTION MADE UNDER FEDERALLY SPONSOREDRESEARCH AND DEVELOPMENT

This invention was made with government support under grants AG012694and AG000538 awarded by the NIH National Institute of Aging. Thegovernment has certain rights in the invention.

BACKGROUND OF THE INVENTION Field of the Invention

Embodiments of the invention relates to treating cognitive dysfunctionin aging, age-related and brain derived neurotrophic factor(BDNF)-dependent disorders. More specifically, the invention relates totreating cognitive dysfunction via administration of a SUV39H1 inhibitorreferred to as ETP69(Rac-(3S,6S,7S,8aS)-6-(benzo[d][1,3]dioxol-5-yl)-2,3,7-trimethyl-1,4-dioxohexahydro-6H-3,8a-epidithiopyrrolo[1,2-c]pyrazine-7-carbonitrile)either alone, or in combination with other cognitive enhancers.

Description of the Related Art

Epigenetic dysregulation is known to contribute to several aspects ofage related memory deficits. In the past few years many studies haveidentified changes in histone methylation states in aging. Methylationof the histone tail typically occurs at specific lysine residues, suchas H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20, and can either activate orrepress transcription. In particular, trimethylation of H3K9 (H3K9me3)is an important repressive histone mark, and is implicated in genesilencing. Establishment of H3K9me3 depends on the activity of thehistone methyl transferase SUV39H1 which regulates H3K9 trimethylationat the peri-centric heterochromatin.

While variations in H3K9 methylation have been suggested to be theunderlying epigenetic mechanism for several age-related changes such assustained vascular inflammation, diabetes, and metabolic memory, thedirect effect of aging on regulation of histone lysine methylation inthe brain has not been explored previously. Nor have there been anystudies, which directly address the effect of SUV39H1 inhibition, andthe corresponding downregulation of H3K9me3 on memory and cognitivefunction. Recent progress in the development of small moleculeinhibitors of methyltransferases and demethylases which regulate thefunction of enzymes that contribute to histone methylation may thus be apowerful means to offset age-related deficits.

There is an urgent need to identify therapies and therapeutic regimesfor cognitive dysfunction, e.g., cognitive deficits related to aging,aged-related disorders and Alzheimer's disease.

BRIEF SUMMARY OF THE INVENTION

One or more embodiments of the invention are directed to use of H3K9me3modulation for enhancing cognitive function in aging and for treatmentof age-related disorders, e.g. dementia and other defects related tobrain and neural functions.

Some recent studies have revealed that histone methyltransferases anddemethylases are implicated in aging and longevity. Methyltransferasescatalyze histone methylation of specific genomic loci. And yet, howhistone methylation contributes to learning and memory in aging hasnever been explored. Trimethylation of H3K9 (H3K9me3) is an importantrepressive histone mark, and is typically implicated in gene silencing.Embodiments of the present invention identify for the first time anessential role for histone H3K9me3 and its histone methyl transferase(SUV39H1) in mediating hippocampal memory functions. Pharmacologicalinhibition of SUV39H1 using a novel and selective inhibitor decreasedlevels of H3K9me3 in the hippocampus of aged animals, and improvedperformance in the object location memory task, fear conditioning taskand in a complex spatial environment learning task. The inhibition ofSUV39H1 induced an increase in spine density of thin and stubby but notmushroom spines in the hippocampus of aged animals and increasedGluR1-containing AMPA receptors levels at spine surface, a key index oflong-term potentiation (LTP).

In addition, there were changes at the BDNF gene promoter regions, inconcert with overall BDNF protein levels in the hippocampus of drugtreated animals compared with control animals. BDNF is a key member ofthe neurotrophin family, and is involved in a wide range ofneurodegenerative diseases including mood disorders, depression, bipolardisorder and neuropsychiatric conditions such as schizophrenia, apartfrom aging. Through various processes such as dendritic arborization,synaptic consolidation, and strengthening TrkB signal transduction, BDNFserves neuronal plasticity, neuronal health and survival in the brain.The data presented here shows that SUV39H1 inhibition mediates BDNFregulation in the brain. Thus the compound may have utility in disordersin addition to those associated with age-related cognitive deficitswhere BDNF levels are inadequate to maintain normal performanceincluding depression, schizophrenia, mood disorders and others.Together, these data demonstrate that SUV39H1 inhibition and theconcomitant H3K9me3 downregulation mediates gene transcription in thehippocampus and reverses age-dependent deficits in hippocampal memory,and can be instrumental in reversing other BDNF-dependent disorders suchas mentioned above but not limited to those above.

A spatial memory task, termed object location memory (OLM), which isknown to be hippocampal dependent was used to evaluate the effects ofH3K9me3 manipulation in aged animals. This was done to determine ifETP69 treatment differentially affects performance accuracy in the OLMtask in a pre-trial versus a post-trial administration paradigm. The preversus post-trial paradigms for the OLM task allows for testing of twodistinct components of spatial memory formation. Specifically, thepre-training drug administration evaluates acquisition and recall ofmemory, while the post training drug administration targets memoryconsolidation and recall. It was found that intraperitoneal injection(“i.p.”) of 10 mg/kg of the drug, administered either approximately 30minutes prior to acquisition phase (pre-trial) or immediately afteracquisition (post-trial) improved performance in the OLM task.

Another test of the effect of the compound on learning and memoryutilized use of a task referred to as the unsupervised learning task(USL). The USL task is a behavioral paradigm in which mice are allowedto freely explore a four-compartment environment for a specified periodof time. Reduction in overall activity and exploration of the test arenaover this time is considered a measure of learning and short-termmemory. If this occurs at similar rates in the two groups, it indicatesno significant differences in short term learning and memory. We foundthat animals treated with ETP 69 (10 mg/kg; i.p.) showed a significantdecrease in habituation/exploration (as measured by distance travelled)24 hours after treatment. One-way ANOVA revealed significant groupdifferences (F_(3,19)=4.05, p<0.05) and post hoc testing confirmed thedifference between performance on Day 1 and Day 2 in ETP 69 treatedanimals (p<0.05) but not in the age matched control group.

In another test, using the contextual fear conditioning test, thecompound was effective in improving hippocampal dependent learning andmemory. We found that aged animals (n=7/group) that had been treatedwith ETP69 showed improved performance on the task compared to agedcontrols (p≤0.01).

Overall, these behavioral data suggest that ETP69 administrationimproves hippocampal-dependent learning and memory over a battery oftests. The data also suggest that other tasks which measure memory andcognitive performance may also be positively affected by administrationof ETP69.

Since the OLM, fear conditioning and USL are all hippocampal specifictask, the total level of H3K9me3 in the hippocampus following drugtreatment in hippocampal tissue samples from the aged animals was alsotested. The results showed significant effect of drug treatment inhistone extracts obtained from the hippocampus of drug treated animals.T-test analysis showed decreases in H3K9me3 levels in animals treatedwith ETP69 (pre-trial, p<0.05).

Embodiments of the present invention provide the first evidence of arole of H3K9me3 in enhancing memory and cognitive function and show thatthis histone methylation mark can be reversed by a pharmacologicalintervention. The studies also provide evidence that by manipulating theenzyme that regulates histone methylation, it is possible to alter thechromatin state of subjects and restore memory function in the agingbrain. Finally, this compound can be used alone or together with variouslifestyle or pharmacological interventions to enhance cognitiveperformance. Cognitive function may be subdivided into and includesubdomains such as memory (including working and episodic memory),learning, executive function, attention, speed of processing, and globalcognitive functions such as activities of daily living, etc. Theapproach using a combination intervention may enhance cognition beyondeither intervention alone.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects, features and advantages of the inventionwill be more apparent from the following more particular descriptionthereof, presented in conjunction with the following drawings wherein:

FIG. 1 illustrates the structure of ETP69(Rac-(3S,6S,7S,8aS)-6-(benzo[d][1,3]dioxol-5-yl)-2,3,7-trimethyl-1,4-dioxohexahydro-6H-3,8a-epidithiopyrrolo[1,2-a]pyrazine-7-carbonitrile).

FIG. 2 is a graphical representation of the effect of the drug at 10mg/kg and 20 mg/kg (i.p.) administered 30 minutes prior to acquisitionphase in the novel place position task in mice.

FIG. 3 is a graphical representation of the results of OLM test showingthe differences in exploration between mice treated with either vehicle,or 10 mg/kg of ETP69.

FIGS. 4A-B are graphical illustrations of the effect of the drug at 10mg/kg (i.p) administered either 30 minutes prior to acquisition phase(Pre-Trial) or immediately after acquisition (Post-Trial) in the novelobject location task in aged mice.

FIGS. 5A-B are graphical illustrations of the effect of the drug at 10mg/kg (i.p) administered either 30 minutes prior to acquisition phase(Pre-Trial) or immediately after acquisition (Post-Trial) in the novelobject location task in young mice.

FIG. 6A is a graphical representation of the effect of ETP69 in theunsupervised learning task.

FIG. 6B is a graphical representation of the effect of ETP69 in theunsupervised learning task.

FIG. 7 is a graphical representation of the effect of ETP69 in the fearconditioning task.

FIG. 8A is a graphical illustration of trimethylation levels of H3K9 inhippocampal extracts of young vs aged mice.

FIG. 8B is a graphical illustration of trimethylation levels of H3K9 incerebellum extracts of young vs aged mice, n=3/group, p<0.05.

FIG. 8C is a graphical representation of trimethylation levels of H3K9in aged mice which had 10 mg/kg of the drug (i.p.) or vehicle, 24 hourspost drug administration, n=7/group, *p<0.05.

FIGS. 9A-C are graphical illustrations of the effect of ETP69 treatmenton spine counts (thin, mushroom and stubby) in the CA1 region of thehippocampus *p<0.05, significantly different compared to age-matchedcontrols (Student's unpaired t test). **p<0.01, significantly differentcompared to age-matched controls (Student's unpaired t test).

FIG. 10 presents representative images showing effect of ETP69 treatmenton spines in the CA1 of the hippocampus.

FIGS. 11 (A) Representative density plot showing size-gatedsynaptosomes; (B) Representative histogram showing an increase in thePSD-95 positive subpopulation of synaptosomes following ETP69 treatment;(C) PSD-95 positive events increase following ETP 69 treatment insynaptosomes obtained from aged mice; (D) Representative density plotsshowing surface GluR1 and PSD-95 expression in size-gated synaptosomes;(E) GluR1 and PSD-95 double-positive events (upper-right quadrant)increase following ETP 69 treatment in synaptosomes obtained from agedmice (p=0.05 vs. aged control mice); (F) Representative density plotsshowing pAkt and PSD-95 in size-gated synaptosomes. pAkt and PSD-95double-positive events (upper-right quadrant) increase following ETP69treatment; (G) pAkt and PSD-95 double-positive events increase followingETP 69 treatment in synaptosomes obtained from aged mice (p<0.05 vs.aged control mice).

FIG. 12A is a graphical illustration of BDNF protein levels in groupswhich had 10 mg/kg of the drug (i.p.) either 30 minutes before, or rightafter the acquisition phase in the OLM task are increased in thehippocampus compared to controls. p<0.01, significantly differentcompared to controls.

FIG. 12B is a graphical representation showing that H3K9me3 levels atExon 1 of BDNF was significantly lower in ETP69 treated animals comparedto controls (p=0.056). n=7 for controls and n=9 for ETP 69 treatedanimals.

FIG. 13 is a graphical illustration of the effect of ETP69 on neuronalsurvival after oxygen-glucose deprivation (OGD).

FIGS. 14A-B are illustrations of the effect of ETP69 on H3K9me3 levelsin 14 DIV hippocampal neurons (A, gel image; B, quantification, n=3, *,p<0.05).

FIG. 15A are images showing ETP69 treatment (20 nM, 24 hours) increasedPSD-95 immunoreactivity 14 DIV hippocampal neurons.

FIG. 15B are images showing ETP69 treatment (20 nM, 24 hours) increaseddendritic F-actin staining (a marker of dendritic spines).

FIG. 16 is an image illustrating ETP69 increased CREB phosphorylation atSer133 measured by Western blotting.

DETAILED DESCRIPTION

The present invention comprising use of H3K9me3 modulation for enhancingcognitive function will now be described. In the following exemplarydescription numerous specific details are set forth in order to providea more thorough understanding of embodiments of the invention. It willbe apparent, however, to an artisan of ordinary skill that the presentinvention may be practiced without incorporating all aspects of thespecific details described herein. Furthermore, although steps orprocesses are set forth in an exemplary order to provide anunderstanding of one or more systems and methods, the exemplary order isnot meant to be limiting. One of ordinary skill in the art wouldrecognize that the steps or processes may be performed in a differentorder, and that one or more steps or processes may be performedsimultaneously or in multiple process flows without departing from thespirit or the scope of the invention. In other instances, specificfeatures, quantities, or measurements well known to those of ordinaryskill in the art have not been described in detail so as not to obscurethe invention. Readers should note that although examples of theinvention are set forth herein, the claims, and the full scope of anyequivalents, are what define the metes and bounds of the invention.

For a better understanding of the disclosed embodiment, its operatingadvantages, and the specified object attained by its uses, referenceshould be made to the accompanying drawings and descriptive matter inwhich there are illustrated exemplary disclosed embodiments. Thedisclosed embodiments are not intended to be limited to the specificforms set forth herein. It is understood that various omissions andsubstitutions of equivalents are contemplated as circumstances maysuggest or render expedient, but these are intended to cover theapplication or implementation.

The term “first”, “second” and the like, herein do not denote any order,quantity or importance, but rather are used to distinguish one elementfrom another, and the terms “a” and “an” herein do not denote alimitation of quantity, but rather denote the presence of at least oneof the referenced item.

The term “dosage unit” as used herein refers to physically discreteunits suitable as unitary dosages for animals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect in association with the required diluent,e.g., a carrier or vehicle. The specifications for the unit dose of thisinvention are dictated by and are directly dependent on (a) the uniquecharacteristics of the active material and (b) the limitations inherentin the art of compounding such active material for therapeutic use inanimals.

The term “therapeutically effective amount” as used herein means thatthe amount of the SUV39H1 inhibitor compound of the present inventioncontained in the composition administered is of sufficient quantity toachieve the intended purpose, such as, in this case, to amelioratecognitive deficits associated with aging, Alzheimer's disease, and otherBDNF-dependent disorders. For the purpose of the present invention,treatment of age related cognitive defects may be measured by reversalsor removal of the hi stone methylation mark. For example, by effectivelyregulating the function of enzymes that contribute to histonemethylation, age-related cognitive deficits may be reversed.

Accordingly, by determining the increase in recall in a patient, one canreadily determine whether the amount of the compound of the presentinvention is therapeutically effective. In one embodiment, thetherapeutically effective amount of the compound ETP69 of the presentinvention may be, for example, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25mg/kg, 30 mg/kg and other suitable values.

One or more embodiments of the invention provides methods to effectivelyameliorate cognitive deficits associated with aging, Alzheimer'sdisease, and other BDNF-dependent disorders using in vivo inhibition ofthe histone methyl transferase SUV39H1 and the consequent trimethylationof histone H3K9 (H3K9me3) down regulation in the aging brain. H3K9me3 isan important repressive histone mark, and is implicated in genesilencing. Establishment of H3K9me3 depends on the activity of thehistone methyl transferase SUV39H1 which regulates H3K9 trimethylationat the peri-centric heterochromatin. Regulating the function of enzymesthat contribute to histone methylation may hence be a powerful means tooffset age-related cognitive deficits. Cognitive deficits associatedwith aging, BDNF dysregulation, and other age related disorders involvedeficits in processing sensory information, attention, acquisition andconsolidation of memory, recall of information, and executive functionssuch as planning, problem-solving, inhibitory control, self-monitoringand other aspects of cognition that would relate to global functionsamong others.

In accordance with one or more embodiments of the present invention, therole of H3K9me3 in learning and memory in an animal model of aging usinga newly developed analog of the epidithiodiketopiperazine alkaloidchaetocin A called ETP69, illustrated in FIG. 1, is studied. Thiscompound, i.e. ETP69, a selective inhibitor of histone methyltransferaseSUV39H1, shows significantly greater selectivity against a panel of 17human histone methytransferases than chaetocin A, the first reportedinhibitor of SUV39H1. In addition, ETP69 exhibits no inhibitory activitytowards histone acetyltransferase p300 and DNA methyltransferase DNMT1.

The hippocampus is critically important for mammalian memory and isknown to be compromised in the aging brain. The data are unequivocalthat hippocampal impairment results in severe deficits in spatialmemory. It has also been suggested that these findings could mean thatspatial memory has singular status with respect to hippocampal function.Thus the studies for this invention used a spatial memory task toevaluate the effects of H3K9me3 manipulation in aged animals. Inaddition, the study employs a spontaneous activity task, referred to asthe unsupervised learning task to extend and confirm these findings.This task measures hippocampal-dependent learning, is known to be highlycorrelated with synaptic changes in the hippocampus, and is susceptibleto age related deficits. Also, another test that has been employed tomeasure the efficacy of the compound is the fear conditioning task. Thistask measures a form of learning and memory in which an aversivestimulus (e.g. an electrical shock) is associated with a particularneutral context (e.g., a room) resulting in the expression of fearresponses to the originally neutral stimulus or context. It is alsoanticipated that other such tasks probing learning and memory would alsobenefit from the drug.

Then in order to identify the downstream cellular/molecular eventsunderlying memory improvements by H3K9me3 inhibition, the studyevaluated the effect of ETP69 on hippocampal spine formation using Golgistaining and flow synaptometry. In accordance with the essential role ofBDNF on activity-dependent spine restructuring, studies of the effect ofETP69 on H3K9 trimethylation of bdnf exons and protein levels inhippocampus, along with Akt activation—a BDNF downstream effector—insynapses the data reveal a novel role for H3K9me3 in memory function andsuggest a specific role in hippocampal dependent memory and learning.

Materials and Methods Animals:

Aged (18-20 months, n=34) or young (3-4 months, n=18) C57B1/6J male micewere group housed with food and water ad libitum, and were acclimated tothe vivarium for one week before experimental procedures. Lights weremaintained on a 12:12 light/dark cycle, and all behavior testing wascarried out during the light phase of the cycle.

Compound:

ETP69(Rac-(3S,6S,7S,8a5)-6-(benzo[d][1,3]dioxol-5-yl)-2,3,7-trimethyl-1,4-dioxohexahydro-6H-3,8a-epidithiopyrrolo[1,2-a]pyrazine-7-carbonitrile),a racemic analog of epidithiodiketopiperazine alkaloids such aschaetocin A, was prepared as described in Overman L E, Baumann M, S.,Nam D, Horne R, Jove L J, Xie C, Kwolik (2014) “Preparation ofEpipolythiodioxopiperazine ETP Derivatives for Treatment of Cancer,” PCTInt., vol. 2014066435, (Int, P., ed), USA [now also published in: M.Baumann, A. P. Dieskau, B. M. Loertscher, M. C. Walton, S. Nam, J. Xie,D. Home, and Larry E. Overman “Tricyclic Analogues ofEpidithiodioxopiperazine Alkaloids with Promising In Vitro and In VivoAntitumor Activity,” Chemical Science, 2015, 6, DOI: 10.1039/C5SC01536G,which is incorporated herein by reference in its entirety, andrecrystallized from methanol. See also PCT Patent Application No.PCT/US2013/066252, entitled “ETP Derivatives,” by Overman et al, whichis also incorporated herein by reference in its entirety. The compoundwas dissolved in a mixture of 50% DMSO based saline solution. Controlsubjects received DMSO based saline solution.

Analogs of ETP69 would include compounds having the formula:

The symbol p is 2, 3 or 4. R¹, R², R³, R⁴, R⁵, R⁶, R¹⁶, and R¹⁸ areindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —Cl₃, —CN,—CHO, —OH, —NH₂, —COOH, —CONH₂, —NO₂, —SH, —SO₂, —SO₂Cl, —SO₃H, —SO₄H,—SO₂NH₂, —NHNH₂, —ONH₂, —NHC(O)NHNH₂, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl.

Testing:

Object Location Memory (OLM):

Training and testing procedures were performed using a standard OLMprotocol. Briefly, 22 aged mice and 18 young mice were handled for about2-3 minutes per day for 5 days, followed by habituation to theexperimental apparatus (white rectangular open field measuring30×23×21.5 cm) for 5 min per day for 5 consecutive days before training.

Dose Response in OLM:

On the test day mice were given 3 minutes of habituation (in an emptytest arena) followed by i.p. injection of ETP69 (10 mg/kg (n=8) or 20mg/kg (n=7)) or vehicle (n=7). Mice were then given a 3-min acquisitiontrial (with 2 similar objects placed in the arena opposite each other)30 minutes after the i.p. injection of drug or vehicle and all animalswere then returned to their home cages for a 24 hour inter-trialinterval. Twenty-four hours later, a 3-minute retention test wasadministered, where one object was moved to a novel location and theamount of time the animals spent exploring the novel versus familiarlocation was recorded in order to evaluate the dose response in the OLMtask. Since animals that had received 10 mg/kg performed better thanother groups in the OLM task, 10 mg/kg was used for the remainder of thestudy. This OLM paradigm has previously shown to be subthreshold forlearning.

Acquisition (Pre-Training) or Consolidation (Post-Training):

In another test, aimed to determine the efficacy of the compound in preand post training paradigms, the same group of 22 aged animals wereretested on the OLM task 3 weeks after the first test. To determinewhether the drug impacted acquisition or consolidation mechanisms, micewere injected with the 10 mg/kg compound (i.p. n=7) or vehicle (n=8).Animals were sacrificed right after retention testing (i.e. 24 hourspost injection), and hippocampi were removed, rapidly frozen on dry ice,and stored at −80° C. until processing for trimethylation levels andBDNF assay. FIG. 2 is a graphical representation of the effect of thedrug at 10 mg/kg and 20 mg/kg (i.p) administered 30 minutes prior toacquisition phase in the novel place position task in mice. The showsthat mice treated with ETP69 at 10 mg/kg and 20 mg/kg (i.p.)administered 30 minutes before acquisition phase in the OLM showed nodifference in object exploration (measured in seconds) in theacquisition phase. Data are mean±SEM; n=7 or 8/group.

18 young mice were also tested in the same OLM paradigm as describedabove. To determine whether the drug impacted acquisition orconsolidation mechanisms, the young mice were injected with the 10 mg/kgcompound or vehicle (i.p, n=6/group), either just before or right afterthe acquisition trial, and tested 24 hours post-acquisition. FIG. 3 is agraphical representation of the results of OLM test showing thedifferences in exploration between mice treated with either vehicle, or10 mg/kg of ETP69. The data shows that in the retention phase of thetask (24 hours after drug administration), mice treated with 10 mg/kg ofETP69 (i.p.) explored the novel object significantly (measured inseconds) more than the familiar object (**p≤0.01, Bonferroni t test).Mice treated with 20 mg/kg of ETP69 performed similar to aged controls.Data are mean±SEM; n=7 or 8/group.

Unsupervised Learning Task:

A new group of 12 aged animals were used for the unsupervised learningtask. Procedures were adapted from published work. The unsupervisedlearning (USL) behavioral apparatus consisted of a large open fielddivided by walls into 4 chambers, all accessible by small entrances ineach dividing wall. The animals can also access a smaller attachedenclosed dark compartment by an open entrance. After 5 days of handling,animals were injected with ETP69 (10 mg/kg, i.p.) or vehicle and placedin the video-monitored USL box for thirty minutes, and the returned tothe home cage. 24 hours later the animals were placed in the USL boxagain and euthanized immediately after. Their brains were rapidlyremoved, hippocampus dissected rapidly, frozen on dry ice, and stored at−80° C. until further processing

Fear Conditioning:

14 aged (18-20 months) male mice were placed in the fear-conditioningchamber were allowed to explore for 2 minutes before receiving oneelectric foot shocks (2 seconds, 0.2 mA). Animals were returned to thehome cage 2 minutes after the foot shock. Twenty-four hours later,behavior in the conditioning chamber was observed for 5 minutes andsubsequently was analyzed for freezing behavior, which was defined asthe absence of all movement except for respiration.

Histone Trimethylation:

Total histone was extracted from frozen hippocampi of 3 young and 3 oldmice using an EpiQuik extraction kit (OP-0006-100) following themanufacturer's protocol. In brief, tissue was weighed and cut into smallpieces and homogenized in 1× prelysis buffer, transferred in a 2-mltube, and centrifuged at 10,000 g for 1 minute at 4° C. The supernatantwas removed; tissue pellet was resuspended in 3 volumes of lysis buffer,incubated on ice for 30 minutes, and centrifuged at 12,000 g for 5minutes at 4° C. Balance-dithiothreitol (DTT) buffer (0.3 volumes) wasadded to the supernatant, which was stored at −80° C. The proteinconcentration of the eluted histone was estimated using a Bradfordprotein detection kit (Bio-Rad, Hercules, Calif.) using BSA as astandard. Histone (H3K9) trimethylation analysis was performed accordingto manufacturer's information (ab115064). Briefly, trimethylatedhistones were captured using specific antibody and detected with alabeled detection antibody, followed by a color development reagent.Absorbance was read at 450 nm, and results were calculated using astandard curve following the manufacturer's instructions.

Spine Counts:

In another series of experiments 10 aged mice (20-22 months) wereinjected with ETP69 (10 mg/kg; i.p) or vehicle (i.p) and 24 hours laterthe animals were euthanized and the brains were separated into twohemispheres. Right hemisphere was used for Golgi staining and the leftwas processed for flow synaptometry. Staining was conducted according tomanufacturer's information (Golgi-Cox, Bioenna).

Flow Synaptometry:

Fresh synaptosome P2 fractions were obtained from whole mousehippocampus using our long-standing protocol. Briefly, the fractionswere obtained from the hippocampus by homogenizing tissue (1:10 w/v) inice-cold sucrose 320 mM. All the steps were carried out at 4° C.;sucrose buffer, grinder, pestle and microfuge tubes were all pre-cooledon ice. Hippocampi were rapidly dissected from a single mouse andhomogenized in 320 mM sucrose (1.5 ml) containing HEPES [10 mM] andprotease/phosphatase inhibitors cocktail, pH 7.4. Homogenizationconsisted of 6-8 manual strokes in a glass-Teflon grinder, clearance(between plunger and glass): 0.15-0.25 mm. Plunger was gently rotatedduring strokes while the grinder was kept on ice. The homogenate wascentrifuged at 1200 g for 10 min. Supernatant (S1, containingmitochondria and synaptosomes) was transferred into two clean microfugetubes and centrifuged at 12,000 g for 20 min. Supernatants (S2) werecarefully removed using a plastic tip and vacuum. Pellets (P2,corresponding to the crude synaptosome fraction) were resuspended bygently pipetting up and down in 1.5 ml of PBS Protein concentration wasdetermined using the BCA assay using bovine serum albumin (BSA) asstandard. Before immunolabeling, all samples were adjusted to the sameprotein concentration using PBS as diluent. Immunolabeling for flowsynaptometry analysis was performed according to a method for stainingof extracellular/intracellular antigens using 200 ul of synaptosomalfractions (50-100 μg protein). Antibodies: GluR1 (extracellular)(Millipore, ABN241, DIL=1:400), p-Akt-ser473 (Cell Signaling, 4060,DIL=1:400), PSD-95 (Millipore, MAB1598, DIL=1:400), anti-rabbit IgGAlexa-488 ad anti-mouse IgG Alexa 647 (Life Science, DIL=1:400). Datawere acquired using a FACS Calibur flow cytometer (BD Biosciences)equipped with argon 488 nm and helium-neon 635 nm lasers. Relative sizeand granularity was determined by forward (FSC) and side scatter (SSC)properties. FSC, SSC, FL1 and FL4 signals were collected using logamplification. Alexa 488 and Alexa 647 fluorochromes were detected bythe FL1 and FL4 detectors, respectively. FSC-SSC plots were used toselect particles matching the size of synaptosomes (0.5-3.0 μm) usingcalibrated beads (FIG. 6A). Identical FSC settings were used foracquiring data on bead standards and samples. Small fragments and debriswere excluded by establishing a FSC-H threshold (325). Ten thousandsize-gated particles were collected and analyzed for each sample.Analysis was performed using the CellQuest Pro software (BDBiosciences).

ELISA for BDNF

ELISA was performed using the BDNF Emax Immunoassay System (G7610,Promega) according to the manufacturer's instructions. Two sets ofsamples were prepared from the hippocampus of each animal, and allreactions were performed in duplicate.

The first series of experiments established that BDNF was a target ofETP69, then brains obtained from a second set of experiments (USL task)were used to detect which BDNF exons were methylated and whichdownstream targets of BDNF showed changes following ETP69 treatment.

ChIP for BDNF Promoter Regions:

After cross-linking with 1% formaldehyde, chromatin was sheared tofragments of 200-500 bp. Immunoprecipitation was realized overnight at4° C. with an antibody directed against histone H3K9me3 (H3K9me3;Millipore). After washes, elution from beads, and reversal of thecross-link, immunoprecipitated DNA was purified and analyzed intriplicate by qRT-PCR with an internal standard curve prepared frompooled input samples. Each sample was normalized with the respectiveinput value. Primers for bdnf promoters for exon I, IV, and VIcorrespond to each unique exon sequence. RT-qPCR primer sets weredesigned using the Roche Universal Probe Library Assay Design Center andobtained from Integrated DNA Technologies (Coralville, Iowa). RT-qPCRreactions were run in a Stratagene MX3005P thermocycler at 95° C. for 3min, followed by 45 cycles of 95° C. for 10 s, and 58° C. for 15 s. EachRT-qPCR run included all samples run in triplicate and a standard curve.Data were analyzed by the 2^(−ΔΔCt) method and expressed as fold changeover control after normalizing with input samples, as describedpreviously.

Statistical Analysis

Mann-Whitney tests were used as non-parametric t-test for paired andunpaired data, respectively and Student test was used for parametricdata. One way ANOVAs were followed by post hoc Tukey's test for meancomparisons of three or more groups; whereas two-way ANOVAs werefollowed by Bonferroni's post hoc test. All statistical tests and thenon-linear fit for FIG. 6B were performed using GraphPad Prism 6. Dataare presented as mean±SEM. p value<0.05 was considered significant.

Results ETP69 in the Object Location Memory (OLM) Task

A dose-response study of the acute effects of intraperitoneallyadministered ETP69 in the spatial, OLM task, was conducted. The doserange included amounts known to be well tolerated in mice. Our resultsdemonstrated that 10 mg/kg but not 20 mg/kg induced memory improvementsin the OLM task in aged mice. This was confirmed using a two-way ANOVA(interaction effect, (F(2,19)=10.25, p<0.01, n=7-8/group)), withpost-hoc testing showing that the group receiving 10 mg/kg of the drugperformed significantly better compared to controls (p<0.05, Bonferronit-test). This is also reflected in the acquisition trial analysis. Theacquisition phase of the testing showed no significant interactioneffect (F(2,19)=0.139, p=NS, n=7-8/group) or main effect of objectlocation (F(1,19)=0.19, p=NS). However, there was a significanttreatment effect (F(2,19)=3.18, p<0.05) with animals that had been givena higher dose of the drug (20 mg/kg) showing a decrease in totalexploration time (p<0.05, Bonferroni t-test). This suggests that higherdoses of the H3K9me3 may impair overall exploration and possibly impairlocomotor activity in aged animals, so that optimal doses should becarefully identified

Next, the studies sought to determine if ETP69 treatment differentiallyaffects performance accuracy in the OLM task in a pre-trial versus apost-trial administration paradigm. The pre versus post-trial paradigmsfor the OLM task allow for testing of two distinct components of memoryformation. Specifically, the pre-training drug administration evaluatesacquisition and recall of memory, while the post training drugadministration targets memory consolidation and recall. Thus, weadministered the drug either 30 minutes before, or immediately after theacquisition phase of the OLM test. We found that 10 mg/kg (i.p) of thedrug, administered either 30 minutes prior to acquisition phase(pre-trial, n=6/group) or immediately after acquisition (post-trial,n=8/group) improved performance in the OLM task (interaction effect(F(2,19)=9.81, p<0.01, FIG. 4b ). Further post-hoc testing showed asignificant effect in both the pre and post-trial groups (p<0.001,Bonferroni t-test). The acquisition phase of the testing, showed nosignificant group differences (interaction F(2,19)=0.26, main effect ofdrug F2,19=0.01, main effect of object location F(1,19)=0.01, p=NS, FIG.4a ).

FIGS. 4A-B are graphical illustrations of the effect of the drug at 10mg/kg (i.p) administered either 30 minutes prior to acquisition phase(Pre-Trial) or immediately after acquisition (Post-Trial) in the novelobject location task in aged mice. No difference in object explorationin the acquisition phase (A). In the retention phase of the task (24hrs±30 minutes, post drug administration), drug treated animals exploredthe novel object significantly more than the familiar object (B)p<0.001, significant difference in time spent exploring novel versusfamiliar object.

To test the hypothesis that H3K9me3 inhibition positively impacts memoryin young and aged mice, the behavioral testing was extended to youngmice. Unlike in aged animals, administration of ETP69 did not improveOLM performance in young mice. 10 mg/kg (i.p) of the drug, administeredeither 30 minutes prior to acquisition phase (pre-trial) or immediatelyafter acquisition (post-trial) did not show any statistical differencescompared to young controls (interaction effect (F(2,15)=0.32, p=NS, maineffect of drug F2,15=2.21, main effect of object location F(2,15)=6.02,p<0.05, FIG. 5B, n=6/group). The acquisition phase of the testing alsoshowed no significant group differences (interaction F(2,15)=0.44, maineffect of drug F(2,15)=25.01, p<0.01, n=6/group) but no differencebetween exploration of POSITION 1 versus POSITION 2 (measured byBonferroni t-test, p=NS, main effect of object location F(2,15)=1.56,FIG. 5A). This suggests that H3K9me3 manipulation may have quitedifferent effects in the young versus aged brain.

FIGS. 5A-B are graphical illustrations of the effect of the drug at 10mg/kg (i.p) administered either 30 minutes prior to acquisition phase(Pre-Trial) or immediately after acquisition (Post-Trial) in the novelobject location task in young mice. No difference in object explorationin the acquisition phase (A) or retention phase of the task (B) (24hrs±30 minutes, post drug administration).

ETP69 in the Unsupervised Learning Task (USL)

To evaluate if H3K9me3 is implicated in measures of spatial learning andto evaluate molecular endpoints, a second series of experiments wasconducted with the USL task being the behavioral endpoint. The USL taskis a simple behavioral paradigm in which mice are allowed to freelyexplore a four-compartment environment for a specified period of time.Reduction in overall activity and exploration of the test arena overthis time is considered a measure of learning and short-term memory. Ifthis occurs at similar rates in the two groups, it indicates nosignificant differences in short term learning and memory. The locomotorpattern of mice reflects the habituation and learning they show, and ishighly correlated with synaptic changes in the hippocampus.

FIG. 6A is a graphical representation of the effect of ETP 69 in theunsupervised learning task. While the aged mice continue to explore thetest arena on both days, aged mice treated with ETP69 (10 mg/kg, i.p.)showed a significant decrease in habituation/exploration (as measured bydistance travelled) on Day 2 compared with Day 1. Aged Control micespent equal time(s) exploring the test arena on both Day 1 and Day 2.Habituation was measured over 30 minutes and data shown are in 5 minutebins *p<0.05, significant difference between habituation/exploration onDay 1 and Day 2 at the specified time points (Tukey's t test). n=5 or6/group.

FIG. 6B is a graphical representation of the effect of ETP 69 in theunsupervised learning task. The graph shows the total distance travelledover 30 minutes on Day 1 and Day 2 following administration of ETP 69(10 mg/kg, i.p.) or vehicle. *p<0.05, significant decrease in totaldistance travelled in 30 minutes between Day 1 and Day 2 (Tukey's ttest). Data are mean±SEM; n=5 or 6/group.

During this test, well-handled mice were placed in the four-compartmenttest box and their movements were monitored for 30 min on Day 1 and thenagain 24 hours later on Day 2. It was determined that animals treatedwith ETP69 (10 mg/kg; i.p.) showed a significant decrease inhabituation/exploration (as measured by distance travelled) 24 hoursafter treatment but not in the first 30 minutes on Day 1 (FIG. 6A).One-way ANOVA revealed significant group differences (F3,19=4.05,p<0.05) and post hoc testing confirmed the difference betweenperformance on Day 1 and Day 2 in ETP69 treated animals (p<0.05) but notin the age matched control group (FIG. 6B, n=5/group). 30 min ofexploration on Day 1 is sufficient to induce some long-term memory ofthe test arena in the mice and can be measured on the Day 2 of testing.We found a difference in activity levels on day 2 and interpret this asimproved retention and recall in ETP69 treated animals even whenlearning remains the same between groups.

ETP69 in the Fear Conditioning Task

In another test, using the contextual fear conditioning test, thecompound was effective in improving hippocampal dependent learning andmemory. We found that aged animals (n=7/group) that had been treatedwith ETP69 showed improved performance on the task compared to agedcontrols (p<0.01). Fear conditioning has been studied in numerousspecies and is often measured with freezing (a period of watchfulimmobility). A number of studies have shown that conditioned fearcoincides substantially with the mechanisms of clinical anxietydisorders. Research into the acquisition, consolidation and extinctionof conditioned fear suggests that this may be a means to treatments foran array of pathological conditions such as dissociation, panic attackdisorder, phobias and even post-traumatic stress disorder in addition tolearning and memory. In addition, it is known that the ventral medialPrefrontal Cortex (mPFC)-basomedial amygdala (BMA) projection implementstop-down control of anxiety state and learned freezing, both at baselineand in stress-induced anxiety, defining a broadly relevant new top-downbehavioral regulation pathway that is relevant for all the abovementioned conditions.

In order to confirm our findings from the OLM and USL tasks, we used thecontextual fear conditioning to test the effect of H3K9me3downregulation on hippocampal dependent learning and memory. Fearconditioning also indicates if amygdala and related functions are alsoregulated. We found that aged animals (n=7/group) that had been treatedwith ETP69 showed improved performance on the task compared to agedcontrols (p<0.01). Overall, these behavioral data suggest that ETP69administration improves hippocampal dependent learning and memory over abattery of tests.

FIG. 7 is a graphical representation of ETP6 in the fear conditioningtask. Aged mice treated with ETP69 (10 mg/kg, i.p.) showed improvedperformance when contextual fear conditioning was assessed. *p=0.01,Bonferroni t-test, Data shown as ±SEM. n=7 per group.

H3K9Me3 Levels in the Hippocampus

We first compared H3K9me3 levels in the hippocampus and cerebellum ofyoung versus old mice and found significantly higher level of H3K9me3 inaged mice in the hippocampus but not in the cerebellum (FIG. 8A, p<0.05,n=3/group). Since the OLM and USL are both hippocampal specific task andwe found a difference in H3K9me3 levels in the hippocampus of youngversus old mice, we tested the total level of H3K9me3 in the hippocampusfollowing drug treatment in hippocampal tissue samples from the cohortof animals described above in the OLM task. Our results showedsignificant effect of the drug in histone extracts from the hippocampusof the drug treated animals. t-test analysis showed decreases in H3K9me3levels in animals treated with ETP69 (p<0.05, n=7/group, FIG. 8B). Incomparison there was no significant difference between levels of H3K9me3in the cerebellum of ETP69-treated versus untreated mice.

H3K9Me3 Inhibition Increases Spine Density and GLuR1 Receptor SurfaceExpression in Hippocampal Synaptosomes

It has been reported that novel memory formation can be associated witha transient increase in spine density in the hippocampus. In particular,improved performance in the OLM and USL tasks is associated withstructural and/or functional changes at excitatory glutamatergicsynapses. Thus, we examined whether pharmacological inhibition of thehistone methyl transferase (SUV39H1) was sufficient to induce anincrease in dendritic spine formation in the hippocampus.

Specifically, we counted and classified spines on CA1 pyramidal neurons.Dendrite segments from neurons in CA1 of the hippocampus were imaged byconfocal microscopy and a blinded investigator counted and classifieddendritic spines according to their morphology. Spines were manuallycounted and classified as thin, mushroom, or stubby, according topreviously described criteria.

For each animal, at least 3 pyramidal neurons and 200 μm of totaldendrite length and 250-500 spines were analyzed (n=5 animals pergroup). All of the neurons were chosen from the dorsal part of the CA1hippocampal region (according with it essential role in spatial memory)and were completely stained along basal and apical dendrites. FIG. 10presents representative images showing effect of ETP69 treatment onspines in the CA1 of the hippocampus. In this illustration, the toppanel shows hippocampal neurons from control animals and the lower panelshows spines observed in ETP69 treated animals.

Segregation analysis was done to differentiate basal from apicaldendrites in the same neuron. On average, ETP69 treated mice had 45%more total number of spines per length of dendrite (μm) compared tocontrols analysis of spine density by morphology revealed asignificantly higher density of thin (p<0.001, Student's t-test), andstubby spines (p<0.05, Student's t-test), in ETP69 treated mice comparedto control mice (FIGS. 9A-C). There was no difference in the numbers ofmushroom spines/length of dendrite measured (FIGS. 9A-C).

Next, we studied the influence of ETP69 on synapses using flowsynaptometry, an innovative approach to molecularly characterizeisolated synaptosomes (presynaptic terminals attached to post-synapticdendritic spines). We focus on the expression of PSD95 (scaffoldingprotein) and GluR1 (subunit of AMPA receptors), as theactivity-dependent spine growth depends on the incorporation of AMPAreceptor at PSD-enriched regions and this process links spine growthwith increased synaptic transmission efficiency. After drug treatment,hippocampal synaptosome fractions were immunostained and analyzed byflow synaptometry. Sample acquisition by flow synaptometry firstidentifies synaptosomes by size using calibrated beads as previouslydescribed. It has been shown that the subset of particles between0.5-3.0 μm is highly enriched in synaptosomes, as indicated by the highlevels of synaptophysin and PSD95 in most (>70%) size-gated particles.Consistent with the ETP69-induced increase in spine numbers (FIGS.9A-C), our analysis on size-gated particles revealed that ETP69increases the proportion of synaptosomes expressing PSD95 (p<0.05, FIG.11C), thus reflecting an increase in the number of synapses. Nodetectable changes were observed in the PSD95 levels per particle, asdetermined by the Mean Fluorescence of intensity. Next, we testedwhether ETP69 increases the relative levels of spines expressing surfaceGluR1-AMPA receptors. We quantified the proportion of size-gatedsynaptosomes co-expressing GluR1 at surface and PSD95 intracellularly bydouble labeling combining extracelullar (no permeablization) andintracellular immunodetection. We found an increase in the amount ofPSD95-positive (PSD95+) events co-expressing surface GluR1 inETP69-treated mice, compared to vehicle-treated controls (p=0.05, FIG.11E). Next, we analyzed the effects of ETP69 on Akt activation (Aktphosphorylation at Serine-473, p-Akt), an essential step for theactivity-dependent transport of PSD95 to dendrites after NMDA receptoractivation. According with the increased proportion of PSD95+GluR1+events after ETP69 treatment, SUV39H1 inhibition by ETP69 also increasedthe proportion of events expressing both p-Akt and PSD-95(p-Akt+PSD95+), relative to samples from vehicle-treated mice (p<0.05,FIG. 11G). Overall these results suggest that H3K9me3 inhibition acts,at least in part, by positively modulating molecular processes thatpromote spine generation and plasticity.

ETP69 Increases H3K9Me3 Levels at BDNF Promoter and BDNF Protein Levelsin Hippocampus of Aged Mice

It stands to reason that if treatment with SUV39H1 inhibitor stimulatesspine formation in the hippocampus, it should also produce gene specificchanges in distinct signaling cascades that correspond to memory. In theadult brain BDNF plays a major role on synapse formation and plasticity,acting at both pre- and postsynaptic sites. Thus we tested the effect ofH3K9me3 downregulation on BDNF, which is critical for consolidation ofhippocampal dependent learning and memory. The bdnf gene is composed ofseveral noncoding exons, each one regulated by its own promoter andresponding to different stimuli. We therefore evaluated whether ETP69treatment decreases trimethylation of H3K9 at bdnf promoters I, IV, andVI. A significant effect of treatment was found for H3K9me3 at bdnf I(p=0.05, Mann-Whitney t-test, n=7 for control, 9 for ETP69, FIG. 12B).Importantly, ETP69-induced epigenetic changes at BDNF promoter wereassociated with an increase of BDNF protein levels in hippocampus. Wefound significantly elevated levels of BDNF in the hippocampus of ETP69treated mice relative to controls (p<0.01 F(2,16)=8.09, ANOVA followedby post hoc Bonferroni t-test; FIG. 12A).

In this study we tested the potential of acute in vivo SUV39H1inhibition and the consequent H3K9me3 down regulation to attenuatelearning and memory deficits in aging. We further evaluated potentialmechanisms which may contribute to cognitive benefits observed followingH3K9me manipulation. Performance in the object location memory task,fear conditioning and the unsupervised learning task was improvedfollowing H3K9me3 downregulation. This corresponded with an increase indendritic spine density of pyramidal neurons and an increase in synapsesexpressing surface GluR1-containing AMPA receptors in the hippocampus.Levels of BDNF were also upregulated in the hippocampus of animals whichhad been administered the SUV39H1 inhibitor, and synaptosomal extractsobtained from the hippocampi of these animals showed increased levels ofphosphorylated Akt. These results therefore provide support for theamelioration of cognitive deficits and suggests that H3K9me3downregulation triggers a cascade of events involving BDNF, spineremodeling and growth.

To the best of our knowledge, there have been no studies which haveevaluated the effect of H3K9me3 inhibition on learning and/or memoryfunction. Here, we present the first evidence that decreased H3K9me3 inthe hippocampus improves spatial memory in aged mice. In both pre- andpost-training paradigms of the OLM task, ETP69-treated animals performedequally well during testing, 24 hours post-acquisition trial. This ledto the conclusion that acute treatment with ETP69 was inducing ahippocampus specific change in H3K9me3 levels in aged animals. Data fromthe USL task confirmed that ETP69 treated animals were showing improvedretention and recall at 24 hours but not at 30 minutes post-drugtreatment, when learning remained the same between groups. Repressorsand cofactors recruited by H3K9me3 include histone deacetylases (HDACs)and heterochromatin protein-1α (HP1α). In fact, HP1 associates directlywith SUV39H1 and leads to a self-sustaining repressive cycle and mayrequire more than 30 minutes to show any behavioral manifestations. Thusthe results are consistent with the hypothesis that changes at themolecular (and hence behavioral levels) are not rapidly engaged, butneed time to evolve the mechanism supporting improved retention andrecall.

Transient increases in spine density have been associated with improvedlearning and memory particularly in the hippocampus of aged mice, butthe effect of H3K9me3 manipulation on synaptic function and spines iscurrently unexplored. Here we report that ETP69 increased both thin andstubby spine count in the CA1 region of ETP69 treated animals. Thinspines are flexible and critical for formation of new synapses whichmakes them well suited for facilitating acute improvements in cognitionobserved with ETP69-treatment. It stands to reason that the behavioralchanges observed following H3K9me3 block was derived in part due tochanges in spine density. Furthermore, remodeling spines requiresincorporation of AMPA receptor at PSD-enriched regions (Park et al.,2004). It has been previously shown that synaptic connections can bestrengthened by addition of AMPA receptor to synapses and that in factit remodeling of spines requires the incorporation of AMPA receptors onsynaptic surface. Our data show that levels of both PSD+ synaptosomesand the PSD95+ synaptosomes expressing surface GluR1 in synapticterminals in hippocampal samples of ETP69 treated animal was increased,thus supporting the hypothesis that H3K9me3 mediates changes to synapticnetwork/signaling in the hippocampus leading to improved cognitivefunction in aging. In addition to its effect on the hippocampus,antagonism of H3K9me3 also leads to upregulation of p-AKT in size-gatedPSD95-containing synaptosomes from the hippocampus. BDNF is a keymolecule serving synaptic plasticity and neuronal activity. We havepreviously shown that HDAC inhibition in the aged brain improves spatialmemory in a BDNF dependent manner. Since HDAC is one of the cofactorsrecruited by H3K9me3, we tested the role of SUV39H1 inhibition on BDNFprotein levels in the aged brain. Our data show, that H3K9me3 modulateslearning and memory and it is likely that this effect is mediated by aBDNF-dependent mechanism. Furthermore, our results suggest that EXON 1alone, drives BDNF upregulation following ETP69 treatment in aged mice.It has been suggested that that differential production of BDNFtranscripts may either affect the function of the protein, or provide ameans for specific regulatory mechanisms in production of BDNF indifferent brain regions. It appears likely that H3K9me3 inhibitionselectively participates in regulation of a BDNF transcript 1, but thedownstream result of this selectivity remains unknown. However, we didnot observe changes in Arc (data not shown). We cannot completely ruleout the possibility that we did not observe changes in Arc because it israpidly induced and decayed, but it is equally likely that there aremultiple changes in synapses following H3K9me3 downregulation and Arcinduction may not be one of them. This study only provides a first lookat cascade of possibilities regulated either directly or indirectly byH3K9me3 inhibition. It is possible that activation of certain molecularpathway following removal of the H3K9me3 repressive mark activateshippocampal-memory pathway(s) which in turn may generate additionaltranscription and translation required for the maintenance of improvedmemory function in aged animals.

The Effects of SUV39H1 Inhibitor ETP69 on Neuronal Survival andFunctions

We sought to establish that ETP69 can act directly on neurons. Unlikecancer cells neurons are non-dividing cells and thus are a distinctcellular target. We used primary neuronal cell cultures which are voidof other cell types and where the concentration of drug can berigorously controlled. Neuronal survival and synaptic growth is a commonmethod to evaluate compounds.

OGD in 14 DIV hippocampal neurons was induced by an approach similar tothat described by Newcomb-Fernandez et al (2001). Normal media wasreplaced with PBS and culture plates were placed in an airtight chamber.The chamber was flushed with N₂ and CO₂ for 3 minutes, sealed, andplaced in a 37° C. incubator for 2 hours. PBS was replaced with DMEM(serum-free) and cultures were returned to a normoxic environment.Culture medium was collected 48 hours after the cultures had returned toa normal environment. The cytotoxicity was measured by LDH assay(Thermo-Fisher). To calculate % Cytotoxicity, subtract the LDH activityof the Spontaneous LDH, release Control (water-treated) from thechemical-treated sample LDH activity, divide by the total LDH activity[(Maximum LDH Release Control activity)−(Spontaneous LDH Release Controlactivity)], and multiply by 100:

${\% \mspace{14mu} {Cytotoxicity}} = {\frac{{{Compound}\text{-}{treated}\mspace{14mu} {LDH}\mspace{14mu} {activity}} - {{Spontaneous}\mspace{14mu} {LDH}\mspace{14mu} {activity}}}{{{Maximum}\mspace{14mu} {LDH}\mspace{14mu} {activity}} - {{Spontaneous}\mspace{14mu} {LDH}\mspace{14mu} {activity}}} \times 100}$

Initially we tested the effect of ETP69 on oxygen-glucose deprivation(OGD)-induced cytotoxicity. Mature hippocampal neurons (14 DIV) weretreated with OGD for 2 hours in the presence or absence of ETP69.Cytotoxicity was measured by LDH assay 48 hours after OGD. ETP69 at 4 nMbut not 100 nM rescued neurons from OGD-induced cytotoxicity. FIG. 13 isa graphical illustration of the effect of ETP69 on neuronal survivalafter oxygen-glucose deprivation (OGD). 14 DIV hippocampal neurons weretreated with OGD for 2 hours in the presence or absence of ETP.Cytotoxicity was measured by LDH assay 48 hours after OGD. Results aremeans±SEM of 4 samples. *, p<0.05.

Next, we examined the effect of ETP69 on H3K9me3 levels in culturedhippocampal neurons. 24 hours of ETP69 treatment resulted in adose-dependent decrease in neuronal H3K9me3 level. FIGS. 14A-B areillustrations of the effect of ETP69 on H3K9me3 levels in 14 DIVhippocampal neurons (FIG. 14A—gel image; FIG. 14B—quantification, n=3,*, p<0.05). As the illustrations show, ETP69 treatment (24 hours)decreased H3K9me3 level measured by Western blotting.

As ETP69 at 20 nM led to greatest decrease in H3K9me3 level, we examinedthe effect of ETP69 at 20 nM on synaptic protein PSD-95 expression andmorphology of dendritic spines. ETP69 treatment increased PSD-95immunoreactivity. FIG. 15A are images showing ETP69 treatment (20 nM, 24hours) increased PSD-95 immunoreactivity (a marker of dendritic spineswhere synapses are made) 14 DIV hippocampal neurons. Neurons werestained with antibodies against PSD-95 (red) and MAP2 (green). Scalebars: 10 μm, top panel; 2 μm, bottom panel.

FIG. 15B are images showing ETP69 treatment (20 nM, 24 hours) increaseddendritic F-actin staining (a marker of dendritic spines). Note presenceof numerous puncta marking presence of many spines. Top panel: Control,bottom panel: ETP treated neurons. Scale bar: 2 μm. This illustrationshows that ETP69 also increased F-actin staining-labeled dendriticspines.

Furthermore, ETP69 treatment increased phosphorylation of transcriptionfactor CREB at Ser133. FIG. 16 is an image illustrating ETP69 increasedCREB phosphorylation at Ser133 measured by Western blotting. CREB is atranscription factor whose activation is involved in synaptic plasticityand memory formation.

These data distinguish the use of ETP on the nervous system and neuronsfrom cancer applications as they demonstrate ETP69 acts on neurons, anon-dividing cell type, to promote their survival, growth and synapticplasticity.

The studies provide evidence of the role of H3K9me3 in enhancing memoryand cognitive function, e.g. age-related memory decline, and show thatthis histone methylation mark can be reversed by a pharmacologicalintervention. The studies also provide evidence that by manipulating theenzyme that regulates histone methylation, it is possible to alter thechromatin state of subjects and restore memory function in in the agingbrain. Finally, this compound can be used alone or together with eithervarious lifestyle interventions, or pharmacological interventions toenhance cognitive performance (i.e. cognitive enhancer), e.g. memory,learning, executive function, attention, speed of processing, globalcognitive functions, activities of daily living, etc. These dualapproaches may enhance cognition beyond either intervention alone. Thiswill also lead to improved functional outcomes such as sleep, pain, andquality of life.

In one or more embodiments, pharmacological cognitive enhancers mayinclude a cholinesterase inhibitor such as tacrine, donepezil,rivastigmine, and galantamine, for example. The pharmacologicalcognitive enhancer may also be an NMDA antagonist or an NMDA agonist, anampakine, a BZD/GABA receptor complex modulator, a serotonin antagonist,a nicotinic class compound, a muscarinic class compound, a PDEinhibitor, a G protein class compound, a channel modulator, animmunotherapeutic class compound, an anti-amyloid or amyloid loweringagent, a statin or a PPARS modulator.

In one or more embodiments, lifestyle cognitive enhancers may includephysical and mental exercises, dietary supplements such as antioxidant,a mitochondrial function enhancer, caffeine, omega-3, andDocosahexaenoic acid (DHA).

In one or more embodiments, the cognitive enhancer may includecombinations of lifestyle and pharmacological interventions.

While the invention herein disclosed has been described by means ofspecific embodiments and applications thereof, numerous modificationsand variations could be made thereto by those skilled in the art withoutdeparting from the scope of the invention set forth in the claims.

What is claimed is:
 1. A method of reversing cognition loss in an animalsubject in need thereof, the method comprising: selecting an animalsubject with cognitive loss; and administering a therapeuticallyeffective amount of a SUV39H1 inhibitor compound to said animal subject,wherein said therapeutically effective amount comprises single dosingfor acute treatment and repeated dosing for chronic treatment.
 2. Amethod of reversing cognition loss in a patient in need thereof, themethod comprising: selecting a patient with loss of memory function; andadministering to the patient a therapeutically effective amount of aSUV39H1 inhibitor compound together with a pharmaceutical cognitiveenhancer, wherein said therapeutically effective amount comprises singledosing for acute treatment and repeated dosing for chronic treatment. 3.The method of claim 2, wherein the cognitive enhancer is acholinesterase inhibitor.
 4. The method of claim 3, wherein thecholinesterase inhibitor is selected from a group comprising tacrine,donepezil, rivastigmine, and galantamine.
 5. The method of claim 2,wherein the cognitive enhancer is an NMDA antagonist or an NMDA agonist.6. The method of claim 2, wherein the cognitive enhancer is an ampakine.7. The method of claim 2, wherein the cognitive enhancer is a BZD/GABAreceptor complex modulator.
 8. The method of claim 2, wherein thecognitive enhancer is a serotonin antagonist.
 9. The method of claim 2,wherein the cognitive enhancer is a nicotinic class compound.
 10. Themethod of claim 2, wherein the cognitive enhancer is a muscarinic classcompound.
 11. The method of claim 2, wherein the cognitive enhancer is aPDE inhibitor.
 12. The method of claim 2, wherein the cognitive enhanceris a G protein class compound.
 13. The method of claim 2, wherein thecognitive enhancer is a channel modulator.
 14. The method of claim 2,wherein the cognitive enhancer is an immunotherapeutic class compound.15. The method of claim 2, wherein the cognitive enhancer is ananti-amyloid or amyloid lowering agent.
 16. The method of claim 2,wherein the cognitive enhancer is a statin or a PPARS modulator.
 17. Amethod of enhancing cognition in a subject in need thereof, the methodcomprising: selecting a subject in need of memory enhancement; andadministering to the subject a therapeutically effective amount of aSUV39H1 inhibitor compound together with a lifestyle cognitive enhancer.18. The method of claim 17, wherein the cognitive enhancer is physicalexercise.
 19. The method of claim 17, wherein the cognitive enhancer ismental exercise.
 20. The method of claim 17, wherein the cognitiveenhancer is dietary supplement.
 21. The method of claim 20, wherein thesupplement is an antioxidant.
 22. The method of claim 20, wherein thesupplement is a mitochondrial function enhancer.
 23. The method of claim20, wherein the supplement is caffeine.
 24. The method of claim 20,wherein the supplement is omega-3.
 25. The method of claim 20, whereinthe supplement is Docosahexaenoic acid (DHA).
 26. A method of treatment,prevention or alleviation of a cognitive dysfunction of a living animalsubject, including a human, the method comprising: selecting a livinganimal subject with signs of cognitive loss; and administering to suchliving animal subject a therapeutically effective amount of a SUV39H1inhibitor compound.
 27. A method of treatment and alleviation of anxietyrelated disorders in an animal subject in need thereof, the methodcomprising: selecting an animal subject with anxiety related disorder;and administering a therapeutically effective amount of a SUV39H1inhibitor compound to said animal subject, wherein said therapeuticallyeffective amount comprises single dosing for acute treatment andrepeated dosing for chronic treatment.